daratumumab,dexamethasone,bortezomib,cyclophosphamide
janssen
['multiplemyeloma', 'emn19', 'mmsm']
results from the phase 2 emn19 study presented in a poster during #eha2023 suggest daravcd is another option for #multiplemyeloma with extramedullary disease. #mmsm 
Oncology news and insights from leading researchers and cancer centers.